{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:56Z","timestamp":1793727896099,"version":"4.6.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) are rare but serious complications associated with long-term use of antiresorptive therapies such as denosumab. Denosumab discontinuation to allow for bone healing is not possible because of the high risk of spontaneous multiple vertebral fractures. We present a case of concurrent AFF and ONJ in a patient previously treated with denosumab 120mg monthly. The patient was managed with a low-dose denosumab regimen tailored according to bone turnover marker monitoring, resulting in successful bone union and resolution of ONJ.<\/jats:p>","DOI":"10.3389\/fendo.2026.1761311","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:08Z","timestamp":1771910348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Atypical femoral fracture and jaw osteonecrosis under high doses of denosumab, healed with the aid of low dose of denosumab: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Hanene","family":"Lassoued","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois (CHUV)","place":["Lausanne, Switzerland"]},{"name":"Bone Unit, Lausanne University Hospital, University of Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lamy","sequence":"additional","affiliation":[{"name":"Bone Unit, Lausanne University Hospital, University of Lausanne","place":["Lausanne, Switzerland"]},{"name":"Universite de Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Francioli","sequence":"additional","affiliation":[{"name":"Department of Maxillofacial Surgery, Lausanne Hospital, CHUV","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonzalez Rodriguez","sequence":"additional","affiliation":[{"name":"Bone Unit, Lausanne University Hospital, University of Lausanne","place":["Lausanne, Switzerland"]},{"name":"Universite de Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux","year":"2022","journal-title":"J Bone Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi","year":"2019","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3\u221223","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"340\u22128","DOI":"10.1002\/jbmr.4472","article-title":"Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis","volume":"37","author":"Everts-Graber","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2270\u221290","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5113","article-title":"Osteonecrosis of the jaw and concomitant atypical femoral fractures with bisphosphonates: A comprehensive literature review","volume":"11","author":"Meyyur Aravamudan","year":"2019","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European calcified tissue society","volume":"105","author":"van de Laarschot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"38\u221248","DOI":"10.11005\/jbm.24.803","article-title":"Incidence of hypercalcemia and vertebral fractures following denosumab withdrawal in lung cancer patients: A longitudinal cohort study","volume":"32","author":"Villanova","year":"2025","journal-title":"J Bone Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"821\u221231","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.03.010","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"307\u221217","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1761311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:09Z","timestamp":1771910349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1761311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":11,"alternative-id":["10.3389\/fendo.2026.1761311"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1761311","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1761311"}}